Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human TNFSF12 Antikörper:
anti-Mouse (Murine) TNFSF12 Antikörper:
anti-Rat (Rattus) TNFSF12 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal TNFSF12 Primary Antibody für FACS - ABIN1176948
Llinàs, Lázaro, de Salort, Matesanz-Isabel, Sintes, Engel: Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry. in Immunology letters 2010
Show all 5 Pubmed References
Human Polyclonal TNFSF12 Primary Antibody für ELISA, IHC - ABIN4363574
Ruiz-Andres, Suarez-Alvarez, Sánchez-Ramos, Monsalve, Sanchez-Niño, Ruiz-Ortega, Egido, Ortiz, Sanz: The inflammatory cytokine TWEAK decreases PGC-1α expression and mitochondrial function in acute kidney injury. in Kidney international 2016
Show all 2 Pubmed References
Human Monoclonal TNFSF12 Primary Antibody für ELISA - ABIN2477010
Chicheportiche, Bourdon, Xu, Hsu, Scott, Hession, Garcia, Browning: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. in The Journal of biological chemistry 1998
Show all 2 Pubmed References
TWEAK:Fn14 binding activates non-canonical NF-kappaB (zeige NFKB1 Antikörper) signaling in prostate cancer cells, stimulating cell invasiveness.
The results suggest that TWEAK/Fn14 (zeige TNFRSF12A Antikörper) interaction directly favors inorganic phosphate-induced vascular smooth muscle cells calcification by activation of both canonical and non-canonical NF-kappaB (zeige NFKB1 Antikörper) pathways.
during psoriatic arthritis (1) serum TWEAK was up regulated and (2) TWEAK-binding autoantibodies are generated.
Plasma TWEAK levels do not reflect disease activity or the grade of inflammation in patients with newly diagnosed inflammatory bowel disease.
TWEAK may contribute to the pathogenesis of BP by reducing BP180 (zeige COL17A1 Antikörper) expression and cellular adherence, involving the activation of ERK (zeige EPHB2 Antikörper) and NF-kappaB (zeige NFKB1 Antikörper) pathways. TWEAK may serve as a biomarker or therapeutic target of BP.
TWEAK upregulated the expression of Fn14 (zeige TNFRSF12A Antikörper).
Fn14 (zeige TNFRSF12A Antikörper) plays a protective role during the acute stages of intestinal inflammation, and its absence promotes the development of colitis-associated cancer.
Fn14 (zeige TNFRSF12A Antikörper).TRAIL can be converted into a highly effective TRAIL oligomer upon binding to TWEAK which induces lymphoblast apoptosis.
Data show that aurintricarboxylic acid (ATA) targets the TNF-related WEAK inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (zeige DDX3X Antikörper) (Fn14 (zeige TNFRSF12A Antikörper)) signaling axis, which could potentially be developed as a new therapeutic agent for treatment of glioblastoma (GBM) patients.
soluble Fn14 (zeige TNFRSF12A Antikörper) may serve as a potential biomarker for both acute and chronic kidney diseases.
TWEAK:Fn14 binding activates non-canonical NF-kappaB (zeige NFKB1 Antikörper) signaling in B16 melanoma cells, inhibiting cell invasiveness.
TWEAK/Fn14 (zeige TNFRSF12A Antikörper) signalling is important in the pathogenesis of ultraviolet B-induced cutaneous disease manifestations in the MRL/lpr (zeige FAS Antikörper) model of lupus.
Disruption of the TWEAK/Fn14 (zeige TNFRSF12A Antikörper) pathway affects several interconnected pathways, including those associated with IL-13 (zeige IL13 Antikörper), IL-33 (zeige IL33 Antikörper), and IL-13Ralpha2, to attenuate 5-fluorouracil-induced intestinal side effects.
TWEAK promotes migration and invasion in murine embryonic fibroblasts through a mechanism dependent on ERKs activation and Fibulin 3 (zeige FBLN3 Antikörper) down-regulation.
These results implicate TWEAK as a potential molecular target for treatment or prevention of inflammatory arthritis and autoimmune diseases such as rheumatoid arthritis.
Findings suggest that TWEAK may contribute to chronic renal changes and renal fibrosis by activating TGF-beta1 (zeige TGFB1 Antikörper) signaling pathway, and phosphorylation of Smad2 (zeige SMAD2 Antikörper) and p38 MAPK (zeige MAPK14 Antikörper) proteins was also involved in this signaling pathway.
TWEAK/Fn14 (zeige TNFRSF12A Antikörper) signaling represses PGC-1alpha expression during acute kidney injury through activation of canonical NF-kappaB (zeige NFKB1 Antikörper) pathways and epigenetic mechanisms including histone deacetylation on NF-kappaB (zeige NFKB1 Antikörper)-binding sites.
These findings suggest that TWEAK signaling might be an aspect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine -mediated neuropathology and be involved in the overall neurodegenerative pathology of Parkinson's disease
results revealed that TWEAK and Fn14 (zeige TNFRSF12A Antikörper) are expressed by uterine natural killer cells in pregnant mice
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is a ligand for the FN14/TWEAKR receptor. This cytokine has overlapping signaling functions with TNF, but displays a much wider tissue distribution. This cytokine, which exists in both membrane-bound and secreted forms, can induce apoptosis via multiple pathways of cell death in a cell type-specific manner. This cytokine is also found to promote proliferation and migration of endothelial cells, and thus acts as a regulator of angiogenesis. Alternative splicing results in multiple transcript variants. Some transcripts skip the last exon of this gene and continue into the second exon of the neighboring TNFSF13 gene\; such read-through transcripts are contained in GeneID 407977, TNFSF12-TNFSF13.
, APO3/DR3 ligand
, TNF-related WEAK inducer of apoptosis
, tumor necrosis factor ligand superfamily member 12
, tumor necrosis factor superfamily member 12
, TNF-related weak inducer of apoptosis